WO2022114724A1 - Composition de milieu pour la production d'exosomes avec une efficacité élevée et une pureté élevée - Google Patents
Composition de milieu pour la production d'exosomes avec une efficacité élevée et une pureté élevée Download PDFInfo
- Publication number
- WO2022114724A1 WO2022114724A1 PCT/KR2021/017257 KR2021017257W WO2022114724A1 WO 2022114724 A1 WO2022114724 A1 WO 2022114724A1 KR 2021017257 W KR2021017257 W KR 2021017257W WO 2022114724 A1 WO2022114724 A1 WO 2022114724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medium
- exosomes
- albumin
- additive
- purity
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 70
- 239000013028 medium composition Substances 0.000 title claims abstract description 23
- 239000002609 medium Substances 0.000 claims abstract description 65
- 210000000130 stem cell Anatomy 0.000 claims abstract description 35
- 102000009027 Albumins Human genes 0.000 claims abstract description 31
- 108010088751 Albumins Proteins 0.000 claims abstract description 31
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 239000000654 additive Substances 0.000 claims abstract description 26
- 230000000996 additive effect Effects 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 21
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 239000007640 basal medium Substances 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 15
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000006143 cell culture medium Substances 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000003550 marker Substances 0.000 description 8
- 102100037904 CD9 antigen Human genes 0.000 description 7
- 102100027221 CD81 antigen Human genes 0.000 description 6
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 101710165845 CD81 protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne un additif pour milieu comprenant de l'albumine et un lipide en tant que principes actifs pour produire des exosomes avec une efficacité et une pureté élevées et une composition de milieu le comprenant et, plus particulièrement, un additif pour milieu comprenant de l'albumine et un lipide en tant que principes actifs pour produire des exosomes avec une efficacité et une pureté élevées, une composition de milieu de culture de cellules souches contenant l'additif pour milieu, et un procédé pour produire des exosomes avec une efficacité et une pureté élevées. Les présents inventeurs ayant identifié l'expansion d'une production d'exosomes dérivés de cellules souches et la séparation d'exosomes très purs à la suite de la culture de cellules dans un milieu contenant de l'albumine et un lipide par le biais d'expériences concrètes, il est possible que le milieu produise des exosomes à haut rendement et à haute pureté, par rapport aux milieux conventionnels. La composition devrait être utilisée comme un moyen efficace dans le domaine du développement de matières premières cosmétiques et d'agents thérapeutiques les utilisant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200162875 | 2020-11-27 | ||
| KR10-2020-0162875 | 2020-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022114724A1 true WO2022114724A1 (fr) | 2022-06-02 |
Family
ID=81756212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2021/017257 WO2022114724A1 (fr) | 2020-11-27 | 2021-11-23 | Composition de milieu pour la production d'exosomes avec une efficacité élevée et une pureté élevée |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022114724A1 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100122087A (ko) * | 2008-02-22 | 2010-11-19 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 입자 |
| US20120093885A1 (en) * | 2010-10-18 | 2012-04-19 | Northwestern University | Therapeutic vesicles |
| KR20150004822A (ko) * | 2012-04-03 | 2015-01-13 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
| US20160108368A1 (en) * | 2014-07-03 | 2016-04-21 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| US20200017825A1 (en) * | 2017-01-23 | 2020-01-16 | Stemcell Technologies Canada Inc. | Media and methods for enhancing the survival and proliferation of stem cells |
-
2021
- 2021-11-23 WO PCT/KR2021/017257 patent/WO2022114724A1/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100122087A (ko) * | 2008-02-22 | 2010-11-19 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 입자 |
| US20120093885A1 (en) * | 2010-10-18 | 2012-04-19 | Northwestern University | Therapeutic vesicles |
| KR20150004822A (ko) * | 2012-04-03 | 2015-01-13 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
| US20160108368A1 (en) * | 2014-07-03 | 2016-04-21 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| US20200017825A1 (en) * | 2017-01-23 | 2020-01-16 | Stemcell Technologies Canada Inc. | Media and methods for enhancing the survival and proliferation of stem cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240050460A1 (en) | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues | |
| Galbraith et al. | Transferrin binding by human lymphoblastoid cell lines and other transformed cells | |
| Djakiew et al. | Pachytene spermatocyte proteins influence Sertoli cell function | |
| Pavlova et al. | Msx1 (Hox-7. 1) in the adult mouse uterus: cellular interactions underlying regulation of expression | |
| JP3253966B2 (ja) | 幹細胞増殖因子 | |
| KR100390340B1 (ko) | 케라티노사이트성장인자산물을함유하는제약학적조성물 | |
| WO2018226051A2 (fr) | Composition de milieu sans sérum pour la culture de cellules comprenant un exosome dérivé d'une cellule souche humaine | |
| WO2013133494A1 (fr) | Fluide de culture de cellules souche d'origine adipeuse, procédé de préparation pour celui-ci, et composition stimulant la croissance des cheveux comprenant celui-ci | |
| Faruqu et al. | Defined serum‐free three‐dimensional culture of umbilical cord‐derived mesenchymal stem cells yields exosomes that promote fibroblast proliferation and migration in vitro | |
| WO2014207679A1 (fr) | Populations cellulaires ayant une activité immunorégulatrice, procédés de préparation et utilisations de celles-ci | |
| McKEITHAN et al. | Multiple forms of tubulin in the cytoskeletal and flagellar microtubules of Polytomella | |
| Woodley et al. | Epidermolysis bullosa acquisita antigen is synthesized by human keratinocytes cultured in serum-free medium | |
| WO2020197059A2 (fr) | Procédé permettant d'induire une différenciation de cellules souches en cellules cartilagineuses, à l'aide d'acide folique, d'un dérivé d'acide folique ou d'un inhibiteur d'acide folique | |
| KR930012104B1 (ko) | 암-관련 항원-특이적 인간 면역 글로불린 및 인간 면역 글로불린을 생산하는 능력을 갖는 인간/인간 하이브리도마 | |
| Feng et al. | Effects of human umbilical cord mesenchymal stem cells derived from exosomes on migration ability of endometrial glandular epithelial cells | |
| KOBAYASHI et al. | Influence of rat hypothalamic extract on gonadotropic activity of cultivated anterior pituitary cells | |
| KR930000188B1 (ko) | 신규 림포카인(lymphokine), 이 림포카인에 특이적인 모노클로날 항체 및 이들의 제조방법 | |
| EP0882787B1 (fr) | Méthode de culture d'hépatocytes. | |
| WO2022114724A1 (fr) | Composition de milieu pour la production d'exosomes avec une efficacité élevée et une pureté élevée | |
| FLAXMAN et al. | Primary cell culture for biochemical studies of human keratinocytes: A method for production of very large numbers of cells without the necessity of subculturing techniques | |
| US4757019A (en) | Method for obtaining pure, stable tissue cultures of human melanocytes | |
| CN1017626B (zh) | 生产新的细胞生长调节因子的方法 | |
| JP3255290B2 (ja) | 幹細胞増殖因子 | |
| KR20120111790A (ko) | 지방유래 중간엽 줄기세포를 연골세포로 분화시키는 방법 | |
| EP0117486A2 (fr) | Méthode de croissance et de purification de lignées de cellules humaines à partir de populations de cellules hétérogènes de tissu en culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21898550 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/10/2023) |